Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell-derived therapies and provides cell processing contract services.

4894 | T

Overview

Corporate Details

ISIN(s):
JP3266030000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507

Description

Cuorips Inc. is a regenerative medicine company that originated as a spin-off from Osaka University. The company specializes in the research, development, and commercialization of cellular and tissue-based products derived from induced pluripotent stem (iPS) cells. Its primary product is a cardiac myocyte sheet, a novel therapy developed for treating severe heart failure. This cardiac tissue sheet, created from iPS cells, is designed to be grafted onto a patient's heart to restore function. In addition to its proprietary product pipeline, Cuorips provides contract services for the development and manufacturing of cell processing products, contributing to the advancement of medical care through cutting-edge technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:13
確認書
Japanese 8.1 KB
2025-11-13 08:07
半期報告書-第10期(2025/04/01-2026/03/31)
Japanese 199.3 KB
2025-06-25 08:39
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
確認書
Japanese 8.1 KB
2025-06-20 08:38
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
確認書
Japanese 8.1 KB
2024-11-14 02:24
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
確認書
Japanese 8.1 KB
2024-06-27 09:36
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
確認書
Japanese 8.1 KB
2024-02-13 07:36
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cuorips Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
Manufactures and supplies chemical pharmaceuticals and biosimilar products.
South Korea
068760
Develops and manufactures medical devices, tissue grafts, and advanced biologics.
South Korea
049180
Celon Pharma S.A. Logo
An integrated pharmaceutical company researching and manufacturing modern drugs.
Poland
CLN
Celularity Inc Logo
Develops allogeneic cell therapies and biomaterials from the human placenta.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Clinical-stage pharmaceutical company developing medicines for unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Immunotherapy company developing engineered T cell therapeutics for cancer treatment.
United States of America
CERO
CERUS CORP Logo
Develops pathogen inactivation technology to reduce transfusion-transmitted infections.
United States of America
CERS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.